GSK's 3-in-1 inhalable drug shows promise in asthma study

British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.

from Reuters: Health News https://reut.rs/2Wk919b
via IFTTT